JP2018506272A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018506272A5 JP2018506272A5 JP2017535019A JP2017535019A JP2018506272A5 JP 2018506272 A5 JP2018506272 A5 JP 2018506272A5 JP 2017535019 A JP2017535019 A JP 2017535019A JP 2017535019 A JP2017535019 A JP 2017535019A JP 2018506272 A5 JP2018506272 A5 JP 2018506272A5
- Authority
- JP
- Japan
- Prior art keywords
- cpp
- alkyl
- seq
- formula
- compound
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims description 53
- 125000000217 alkyl group Chemical group 0.000 claims description 28
- 230000008685 targeting Effects 0.000 claims description 25
- 150000003839 salts Chemical class 0.000 claims description 24
- -1 4-methoxytrityl Chemical group 0.000 claims description 21
- ISAKRJDGNUQOIC-UHFFFAOYSA-N Uracil Chemical compound O=C1C=CNC(=O)N1 ISAKRJDGNUQOIC-UHFFFAOYSA-N 0.000 claims description 20
- RWQNBRDOKXIBIV-UHFFFAOYSA-N thymine Chemical compound CC1=CNC(=O)NC1=O RWQNBRDOKXIBIV-UHFFFAOYSA-N 0.000 claims description 20
- 108010078777 Colistin Proteins 0.000 claims description 16
- 125000002252 acyl group Chemical group 0.000 claims description 16
- JORAUNFTUVJTNG-BSTBCYLQSA-N n-[(2s)-4-amino-1-[[(2s,3r)-1-[[(2s)-4-amino-1-oxo-1-[[(3s,6s,9s,12s,15r,18s,21s)-6,9,18-tris(2-aminoethyl)-3-[(1r)-1-hydroxyethyl]-12,15-bis(2-methylpropyl)-2,5,8,11,14,17,20-heptaoxo-1,4,7,10,13,16,19-heptazacyclotricos-21-yl]amino]butan-2-yl]amino]-3-h Polymers CC(C)CCCCC(=O)N[C@@H](CCN)C(=O)N[C@H]([C@@H](C)O)CN[C@@H](CCN)C(=O)N[C@H]1CCNC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCN)NC(=O)[C@H](CCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@H](CCN)NC1=O.CCC(C)CCCCC(=O)N[C@@H](CCN)C(=O)N[C@H]([C@@H](C)O)CN[C@@H](CCN)C(=O)N[C@H]1CCNC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCN)NC(=O)[C@H](CCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@H](CCN)NC1=O JORAUNFTUVJTNG-BSTBCYLQSA-N 0.000 claims description 16
- XDJYMJULXQKGMM-UHFFFAOYSA-N polymyxin E1 Natural products CCC(C)CCCCC(=O)NC(CCN)C(=O)NC(C(C)O)C(=O)NC(CCN)C(=O)NC1CCNC(=O)C(C(C)O)NC(=O)C(CCN)NC(=O)C(CCN)NC(=O)C(CC(C)C)NC(=O)C(CC(C)C)NC(=O)C(CCN)NC1=O XDJYMJULXQKGMM-UHFFFAOYSA-N 0.000 claims description 16
- 125000005647 linker group Chemical group 0.000 claims description 14
- 125000002221 trityl group Chemical group [H]C1=C([H])C([H])=C([H])C([H])=C1C([*])(C1=C(C(=C(C(=C1[H])[H])[H])[H])[H])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 claims description 14
- PYHYGIPVYYRJHU-LPGHPFMSSA-N (2s,3r)-2-amino-n-[(2s)-4-amino-1-oxo-1-[[(3s,6s,9s,12s,15s,18s,21s)-6,9,18-tris(2-aminoethyl)-15-benzyl-3-[(1r)-1-hydroxyethyl]-12-(2-methylpropyl)-2,5,8,11,14,17,20-heptaoxo-1,4,7,10,13,16,19-heptazacyclotricos-21-yl]amino]butan-2-yl]-3-hydroxybutanamid Polymers N1C(=O)[C@H](CCN)NC(=O)[C@@H](NC(=O)[C@H](CCN)NC(=O)[C@@H](N)[C@@H](C)O)CCNC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCN)NC(=O)[C@H](CCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H]1CC1=CC=CC=C1 PYHYGIPVYYRJHU-LPGHPFMSSA-N 0.000 claims description 12
- 108700026839 polymyxin B nonapeptide Proteins 0.000 claims description 12
- 229940113082 thymine Drugs 0.000 claims description 10
- 229940035893 uracil Drugs 0.000 claims description 10
- 108010093965 Polymyxin B Proteins 0.000 claims description 8
- 241000589517 Pseudomonas aeruginosa Species 0.000 claims description 8
- YKQOSKADJPQZHB-YNWHQGOSSA-N n-[(2s)-4-amino-1-[[(2s,3r)-1-[[(2s)-4-amino-1-oxo-1-[[(3s,6s,9s,12s,15r,18s,21s)-6,9,18-tris(2-aminoethyl)-3-[(1s)-1-hydroxyethyl]-12,15-bis(2-methylpropyl)-2,5,8,11,14,17,20-heptaoxo-1,4,7,10,13,16,19-heptazacyclotricos-21-yl]amino]butan-2-yl]amino]-3-h Polymers CCC(C)CCCC(=O)N[C@@H](CCN)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCN)C(=O)N[C@H]1CCNC(=O)[C@H]([C@H](C)O)NC(=O)[C@H](CCN)NC(=O)[C@H](CCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@H](CCN)NC1=O YKQOSKADJPQZHB-YNWHQGOSSA-N 0.000 claims description 8
- 229920000024 polymyxin B Polymers 0.000 claims description 8
- 229960005266 polymyxin b Drugs 0.000 claims description 8
- 125000004485 2-pyrrolidinyl group Chemical group [H]N1C([H])([H])C([H])([H])C([H])([H])C1([H])* 0.000 claims description 7
- 101150004974 ACP3 gene Proteins 0.000 claims description 7
- 241000023308 Acca Species 0.000 claims description 7
- 101150029029 CAVIN4 gene Proteins 0.000 claims description 7
- 101100000438 Mus musculus Acacb gene Proteins 0.000 claims description 7
- 101100426065 Mus musculus Trim54 gene Proteins 0.000 claims description 7
- 210000000170 cell membrane Anatomy 0.000 claims description 7
- 230000000295 complement effect Effects 0.000 claims description 7
- 108020004999 messenger RNA Proteins 0.000 claims description 7
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 7
- 210000004899 c-terminal region Anatomy 0.000 claims description 6
- 208000032536 Pseudomonas Infections Diseases 0.000 claims description 4
- UCMIRNVEIXFBKS-UHFFFAOYSA-N beta-alanine Chemical group NCCC(O)=O UCMIRNVEIXFBKS-UHFFFAOYSA-N 0.000 claims description 4
- 229910052760 oxygen Inorganic materials 0.000 claims description 4
- 239000001301 oxygen Substances 0.000 claims description 4
- 230000002265 prevention Effects 0.000 claims description 4
- 239000003814 drug Substances 0.000 claims description 3
- 239000003937 drug carrier Substances 0.000 claims description 3
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 2
- SLXKOJJOQWFEFD-UHFFFAOYSA-N 6-aminohexanoic acid Chemical group NCCCCCC(O)=O SLXKOJJOQWFEFD-UHFFFAOYSA-N 0.000 claims description 2
- 229960002684 aminocaproic acid Drugs 0.000 claims description 2
- 229940000635 beta-alanine Drugs 0.000 claims description 2
- 239000003795 chemical substances by application Substances 0.000 claims description 2
- 239000012634 fragment Substances 0.000 claims description 2
- 239000002773 nucleotide Substances 0.000 claims description 2
- 125000003729 nucleotide group Chemical group 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims description 2
- 230000003115 biocidal effect Effects 0.000 claims 2
- 239000003242 anti bacterial agent Substances 0.000 claims 1
- 230000001580 bacterial effect Effects 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 201000003883 Cystic fibrosis Diseases 0.000 description 2
- 238000002648 combination therapy Methods 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- VHNZDWLFXDSLGB-UHFFFAOYSA-N CN(C)P(N(CC1)CCN1C(OCCOCCOCCO)=O)(OC=[IH])=O Chemical compound CN(C)P(N(CC1)CCN1C(OCCOCCOCCO)=O)(OC=[IH])=O VHNZDWLFXDSLGB-UHFFFAOYSA-N 0.000 description 1
- 238000000034 method Methods 0.000 description 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2021202636A JP2022040131A (ja) | 2014-12-31 | 2021-12-14 | アンチセンス抗細菌性化合物および方法 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462098713P | 2014-12-31 | 2014-12-31 | |
| US62/098,713 | 2014-12-31 | ||
| PCT/US2015/000280 WO2016108930A2 (en) | 2014-12-31 | 2015-12-23 | Antisense antibacterial compounds and methods |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021202636A Division JP2022040131A (ja) | 2014-12-31 | 2021-12-14 | アンチセンス抗細菌性化合物および方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018506272A JP2018506272A (ja) | 2018-03-08 |
| JP2018506272A5 true JP2018506272A5 (https=) | 2019-02-07 |
| JP6994941B2 JP6994941B2 (ja) | 2022-02-04 |
Family
ID=56285129
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017535019A Active JP6994941B2 (ja) | 2014-12-31 | 2015-12-23 | アンチセンス抗細菌性化合物および方法 |
| JP2021202636A Withdrawn JP2022040131A (ja) | 2014-12-31 | 2021-12-14 | アンチセンス抗細菌性化合物および方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021202636A Withdrawn JP2022040131A (ja) | 2014-12-31 | 2021-12-14 | アンチセンス抗細菌性化合物および方法 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US11293024B2 (https=) |
| EP (1) | EP3240794A4 (https=) |
| JP (2) | JP6994941B2 (https=) |
| AU (1) | AU2015372560B2 (https=) |
| CA (2) | CA3249464A1 (https=) |
| HK (1) | HK1246303A1 (https=) |
| WO (1) | WO2016108930A2 (https=) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2948373A1 (en) | 2014-05-16 | 2015-11-19 | Oregon State University | Antisense antibacterial compounds and methods |
| CA2948568A1 (en) | 2014-05-19 | 2015-11-26 | David Greenberg | Antisense antibacterial compounds and methods |
| EP3240794A4 (en) | 2014-12-31 | 2018-10-31 | Oregon State University | Antisense antibacterial compounds and methods |
| AU2016379399B2 (en) | 2015-12-23 | 2022-12-08 | Board Of Regents, The University Of Texas System | Antisense antibacterial compounds and methods |
| US11142764B2 (en) | 2015-12-23 | 2021-10-12 | Board Of Regents, The University Of Texas System | Antisense antibacterial compounds and methods |
| WO2020035620A1 (en) * | 2018-08-17 | 2020-02-20 | Centre National De La Recherche Scientifique (Cnrs) | Rna-based therapeutic methods to protect animals against pathogenic bacteria and / or promote beneficial effects of symbiotic and commensal bacteria |
| GB2579253A (en) | 2018-11-28 | 2020-06-17 | Pedanius Therapeutics Ltd | Antibacterial antisense agents |
Family Cites Families (50)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS5668616A (en) * | 1979-11-08 | 1981-06-09 | Yukio Kimura | Preparation of antibiotic composition |
| US5185444A (en) | 1985-03-15 | 1993-02-09 | Anti-Gene Deveopment Group | Uncharged morpolino-based polymers having phosphorous containing chiral intersubunit linkages |
| US5034506A (en) | 1985-03-15 | 1991-07-23 | Anti-Gene Development Group | Uncharged morpholino-based polymers having achiral intersubunit linkages |
| US5217866A (en) | 1985-03-15 | 1993-06-08 | Anti-Gene Development Group | Polynucleotide assay reagent and method |
| WO1986005519A1 (en) | 1985-03-15 | 1986-09-25 | James Summerton | Polynucleotide assay reagent and method |
| US5521063A (en) | 1985-03-15 | 1996-05-28 | Antivirals Inc. | Polynucleotide reagent containing chiral subunits and methods of use |
| US5506337A (en) | 1985-03-15 | 1996-04-09 | Antivirals Inc. | Morpholino-subunit combinatorial library and method |
| US5166315A (en) | 1989-12-20 | 1992-11-24 | Anti-Gene Development Group | Sequence-specific binding polymers for duplex nucleic acids |
| AU659482B2 (en) | 1991-06-28 | 1995-05-18 | Massachusetts Institute Of Technology | Localized oligonucleotide therapy |
| WO1997022371A1 (en) | 1995-12-18 | 1997-06-26 | Collagen Corporation | Crosslinked polymer compositions and methods for their use |
| US6245747B1 (en) | 1996-03-12 | 2001-06-12 | The Board Of Regents Of The University Of Nebraska | Targeted site specific antisense oligodeoxynucleotide delivery method |
| WO1998050557A1 (en) * | 1997-05-02 | 1998-11-12 | University Of Guelph | Proteins involved in the synthesis and assembly of core lipopolysaccharide of pseudomonas aeruginosa |
| WO2000015265A1 (en) * | 1998-09-16 | 2000-03-23 | Vitagenix, Inc. | Compositions and methods of use of uptake mechanisms for diagnostic and therapeutic applications of oligonucleotides targeting bacteria |
| US20040033972A1 (en) * | 2000-12-20 | 2004-02-19 | Horwitz Marcus A. | Treatment of mycobacterium tuberculosis with antisense polynucleotides |
| US20060241075A1 (en) | 2001-05-18 | 2006-10-26 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of desmoglein gene expression using short interfering nucleic acid (siNA) |
| US20040029129A1 (en) | 2001-10-25 | 2004-02-12 | Liangsu Wang | Identification of essential genes in microorganisms |
| US6965025B2 (en) | 2001-12-10 | 2005-11-15 | Isis Pharmaceuticals, Inc. | Antisense modulation of connective tissue growth factor expression |
| CA2522184A1 (en) | 2003-04-17 | 2004-11-04 | The Trustees Of Columbia University In The City Of New York | Desmoglein 4 is a novel gene involved in hair growth |
| US7468418B2 (en) | 2003-04-29 | 2008-12-23 | Avi Biopharma., Inc. | Compositions for enhancing transport of molecules into cells |
| US20050288246A1 (en) | 2004-05-24 | 2005-12-29 | Iversen Patrick L | Peptide conjugated, inosine-substituted antisense oligomer compound and method |
| EP2351839A3 (en) | 2004-07-02 | 2011-10-05 | AVI BioPharma, Inc. | Antisense antibacterial method and compound |
| US20070154896A1 (en) | 2005-02-11 | 2007-07-05 | International Business Machines Corporation | System and method for identification of MicroRNA target sites and corresponding targeting MicroRNA sequences |
| US8067571B2 (en) | 2005-07-13 | 2011-11-29 | Avi Biopharma, Inc. | Antibacterial antisense oligonucleotide and method |
| US7790694B2 (en) | 2005-07-13 | 2010-09-07 | Avi Biopharma Inc. | Antisense antibacterial method and compound |
| WO2007009094A2 (en) | 2005-07-13 | 2007-01-18 | Avi Biopharma, Inc. | Antisense antibacterial method and compound |
| WO2007025016A1 (en) | 2005-08-25 | 2007-03-01 | Texas Tech University System | Inhibition of metallo-beta-lactamase by double-stranded dna |
| WO2009005793A2 (en) | 2007-06-29 | 2009-01-08 | Avi Biopharma, Inc. | Tissue specific peptide conjugates and methods |
| US20100016215A1 (en) * | 2007-06-29 | 2010-01-21 | Avi Biopharma, Inc. | Compound and method for treating myotonic dystrophy |
| US8299206B2 (en) | 2007-11-15 | 2012-10-30 | Avi Biopharma, Inc. | Method of synthesis of morpholino oligomers |
| RU2606627C2 (ru) | 2007-11-15 | 2017-01-10 | Серепта Терапьютикс,Инк. | Способ синтеза морфолиновых олигомеров |
| US8076476B2 (en) | 2007-11-15 | 2011-12-13 | Avi Biopharma, Inc. | Synthesis of morpholino oligomers using doubly protected guanine morpholino subunits |
| WO2009139635A1 (en) * | 2008-05-15 | 2009-11-19 | Prosensa Technologies B.V. | Polymyxin derivatives and uses thereof |
| WO2010134939A2 (en) * | 2008-12-19 | 2010-11-25 | Zirus, Inc. | Mammalian genes involved in infection |
| US20110269665A1 (en) | 2009-06-26 | 2011-11-03 | Avi Biopharma, Inc. | Compound and method for treating myotonic dystrophy |
| US9914745B2 (en) | 2009-08-14 | 2018-03-13 | Indian Association For The Cultivation Of Science | Morpholino-based antisense agent |
| US10017763B2 (en) | 2010-09-03 | 2018-07-10 | Sarepta Therapeutics, Inc. | dsRNA molecules comprising oligonucleotide analogs having modified intersubunit linkages and/or terminal groups |
| ES2607603T3 (es) | 2010-09-30 | 2017-04-03 | Nippon Shinyaku Co., Ltd. | Derivado de ácido morfolino nucleico |
| AU2011326364B2 (en) | 2010-11-12 | 2016-08-11 | Sarepta Therapeutics, Inc. | Antisense antibacterial compounds and methods |
| US20120213663A1 (en) | 2011-02-23 | 2012-08-23 | King Fahd University Of Petroleum And Minerals | Method of removing e. coli bacteria from an aqueous solution |
| US9161948B2 (en) * | 2011-05-05 | 2015-10-20 | Sarepta Therapeutics, Inc. | Peptide oligonucleotide conjugates |
| CA3092114A1 (en) | 2011-05-05 | 2012-11-08 | Sarepta Therapeutics, Inc. | Peptide oligonucleotide conjugates |
| KR101317263B1 (ko) | 2011-07-05 | 2013-10-10 | (주)지노첵 | 리얼타임 ｐｃｒ을 이용한 카바페넴 내성 장내균 검사 방법 및 키트 |
| WO2013011072A1 (en) | 2011-07-20 | 2013-01-24 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Carbapenemase and antibacterial treatment |
| HK1201514A1 (en) * | 2011-11-18 | 2015-09-04 | Sarepta Therapeutics, Inc. | Functionally-modified oligonucleotides and subunits thereof |
| KR101450751B1 (ko) * | 2012-07-05 | 2014-10-16 | 서강대학교산학협력단 | 미생물을 이용한 지방산 제조 방법 |
| CA2948373A1 (en) | 2014-05-16 | 2015-11-19 | Oregon State University | Antisense antibacterial compounds and methods |
| CA2948568A1 (en) | 2014-05-19 | 2015-11-26 | David Greenberg | Antisense antibacterial compounds and methods |
| EP3240794A4 (en) | 2014-12-31 | 2018-10-31 | Oregon State University | Antisense antibacterial compounds and methods |
| AU2016379399B2 (en) | 2015-12-23 | 2022-12-08 | Board Of Regents, The University Of Texas System | Antisense antibacterial compounds and methods |
| US11142764B2 (en) | 2015-12-23 | 2021-10-12 | Board Of Regents, The University Of Texas System | Antisense antibacterial compounds and methods |
-
2015
- 2015-12-23 EP EP15875820.1A patent/EP3240794A4/en active Pending
- 2015-12-23 JP JP2017535019A patent/JP6994941B2/ja active Active
- 2015-12-23 CA CA3249464A patent/CA3249464A1/en active Pending
- 2015-12-23 CA CA2972653A patent/CA2972653C/en active Active
- 2015-12-23 HK HK18105904.4A patent/HK1246303A1/zh unknown
- 2015-12-23 US US15/540,387 patent/US11293024B2/en active Active
- 2015-12-23 AU AU2015372560A patent/AU2015372560B2/en active Active
- 2015-12-23 WO PCT/US2015/000280 patent/WO2016108930A2/en not_active Ceased
-
2021
- 2021-12-14 JP JP2021202636A patent/JP2022040131A/ja not_active Withdrawn